Your browser is no longer supported. Please, upgrade your browser.
Settings
AERI Aerie Pharmaceuticals, Inc. daily Stock Chart
AERI [NASD]
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.19 Insider Own1.70% Shs Outstand48.67M Perf Week1.59%
Market Cap1.19B Forward P/E- EPS next Y-1.00 Insider Trans- Shs Float40.96M Perf Month10.88%
Income-232.00M PEG- EPS next Q-0.76 Inst Own- Short Float16.90% Perf Quarter-39.29%
Sales48.40M P/S24.49 EPS this Y-35.90% Inst Trans2.18% Short Ratio8.43 Perf Half Y-37.08%
Book/sh3.43 P/B7.10 EPS next Y65.80% ROA-85.00% Target Price63.11 Perf Year-61.83%
Cash/sh- P/C- EPS next 5Y- ROE-109.90% 52W Range20.72 - 64.25 Perf YTD-32.55%
Dividend- P/FCF- EPS past 5Y2.60% ROI-92.10% 52W High-63.07% Beta0.37
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin96.60% 52W Low14.53% ATR1.46
Employees353 Current Ratio2.50 Sales Q/Q558.30% Oper. Margin- RSI (14)48.84 Volatility6.54% 6.50%
OptionableYes Debt/Eq0.00 EPS Q/Q26.00% Profit Margin- Rel Volume0.58 Prev Close24.35
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout- Avg Volume821.62K Price23.73
Recom1.90 SMA204.18% SMA50-7.79% SMA200-37.57% Volume47,792 Change-2.55%
Aug-08-19Reiterated Needham Buy $74 → $54
Aug-08-19Reiterated Cantor Fitzgerald Overweight $85 → $62
Mar-21-19Initiated Piper Jaffray Overweight $80
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
Mar-09-17Downgrade Raymond James Strong Buy → Mkt Perform
Mar-08-17Reiterated RBC Capital Mkts Outperform $54 → $55
Mar-08-17Reiterated Needham Buy $52 → $58
Feb-17-17Initiated ROTH Capital Buy $69
Nov-01-16Initiated Aegis Capital Buy
Oct-28-16Reiterated RBC Capital Mkts Outperform $48 → $49
Oct-06-16Reiterated Stifel Buy $50 → $55
Sep-20-16Initiated H.C. Wainwright Buy $66
Sep-15-16Reiterated Stifel Buy $40 → $50
Sep-15-16Reiterated RBC Capital Mkts Outperform $51 → $55
Aug-20-19 06:30AM  Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Business Wire -5.78%
Aug-19-19 01:56PM  Zuckerberg Sells Shares of Facebook GuruFocus.com
Aug-11-19 02:58AM  Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-19 04:08PM  This Biotech Crashed On 'Erroneous' Report Plus 2 Stocks That Diverged Investor's Business Daily +6.65%
09:25AM  Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance Zacks
09:02AM  Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St.
01:50AM  Aerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 06:05PM  Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire
Jul-31-19 10:36AM  Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-28-19 09:23PM  Analysts Recommend Buying These 2 Falling Knives GuruFocus.com
Jul-25-19 07:30AM  Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019 Business Wire
Jul-18-19 06:26PM  Allergan Announces FDA Acceptance of Glaucoma Candidate NDA Zacks
08:22AM  Hatteras Ventures-backed firm adds fresh round of capital American City Business Journals
Jul-11-19 06:46AM  How a Durham firm stands to benefit from an unexpected break in a Japanese trial American City Business Journals
Jul-09-19 05:48PM  Aerie Completes Enrollment Under Rhopressa Study in Japan Zacks
06:30AM  Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule Business Wire
Jun-24-19 08:50AM  Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza Zacks
Jun-20-19 07:09PM  Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy? Insider Monkey
Jun-17-19 09:47PM  Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
06:30AM  Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting Business Wire
Jun-11-19 07:30AM  Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire
Jun-06-19 01:58PM  Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price? Simply Wall St. -6.09%
09:31AM  Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report? Zacks
May-28-19 07:30AM  Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-21-19 05:36PM  Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint Zacks
May-08-19 02:45PM  Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates Zacks +7.50%
May-07-19 10:46PM  Aerie Pharmaceuticals, Inc. (AERI) Q1 2019 Earnings Call Transcript Motley Fool -5.37%
06:15PM  Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:09PM  Aerie: 1Q Earnings Snapshot Associated Press
04:01PM  Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-03-19 02:42PM  Another $100 million 'safety net' set for this Triangle pharma American City Business Journals
May-02-19 06:33PM  Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M Business Wire
12:42PM  Heres What Hedge Funds Think About Aerie Pharmaceuticals Inc (AERI) Insider Monkey
May-01-19 12:00PM  With profits in sight, Durham pharma launches new trials American City Business Journals
06:30AM  Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives Business Wire
Apr-30-19 07:30AM  Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019 Business Wire
Apr-25-19 06:30AM  Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant Business Wire
Apr-11-19 10:05AM  Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside TheStreet.com
Apr-10-19 12:05PM  Have Insiders Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares This Year? Simply Wall St.
Apr-02-19 07:30AM  Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference Business Wire
Apr-01-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe Business Wire
Mar-28-19 05:07PM  Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain? Zacks
Mar-27-19 09:30AM  Aerie (AERI) Down 2.9% Since Last Earnings Report: Can It Rebound? Zacks
Mar-25-19 06:30AM  Aerie Pharmaceuticals Announces Four Appointments Business Wire
Mar-22-19 11:23AM  Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan Zacks
Mar-21-19 06:30AM  Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing Business Wire +7.39%
Mar-19-19 12:28PM  Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105 Zacks
Mar-18-19 06:30AM  Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Business Wire
Mar-13-19 12:50PM  Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma Zacks
07:27AM  The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie Benzinga
Mar-12-19 06:30PM  Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance Business Wire
06:20PM  Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension Business Wire
Mar-07-19 08:13AM  Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years Simply Wall St.
Mar-05-19 07:30AM  Aerie Pharmaceuticals to Present at Two Investor Conferences in March Business Wire
Mar-01-19 08:25AM  New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
06:18AM  Edited Transcript of AERI earnings conference call or presentation 25-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-26-19 10:34AM  Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction Zacks +14.81%
Feb-25-19 09:13PM  Aerie Pharmaceuticals Inc (AERI) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update Business Wire
Feb-22-19 01:55PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs Benzinga
Feb-19-19 07:30AM  Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019 Business Wire
Feb-05-19 02:25PM  Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Feb-04-19 04:56AM  Aerie Pharmaceuticals Enters Overbought Territory: Is A Drop Coming? Zacks
Jan-18-19 09:10AM  Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies Zacks
Jan-17-19 11:47AM  A Spotlight On Aerie Pharmaceuticals, Inc.s (NASDAQ:AERI) Fundamentals Simply Wall St.
06:30AM  Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant) Business Wire
05:14AM  How to spot risky biotech companies and six to avoid now MarketWatch
Jan-07-19 04:57PM  Aerie's Rhopressa Succeeds in Study on Japanese Patients Zacks +6.91%
Jan-04-19 06:30AM  Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan Business Wire
Jan-02-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access Business Wire
Dec-12-18 02:48PM  Aerie Division's Prospects Have Analysts Bullish On American Eagle Benzinga
12:58AM  Hedge Funds Are Selling Aerie Pharmaceuticals Inc (AERI) Insider Monkey
Dec-06-18 08:46AM  Should You Get Rid of Aerie Pharmaceuticals (AERI) Now? Zacks
Dec-04-18 07:20AM  Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar Discovering Underlying Factors of Influence GlobeNewswire
Nov-19-18 02:08PM  Mariko Gordon's Top 5 New Buys GuruFocus.com
Nov-13-18 06:26AM  Aerie Pharmaceuticals (AERI): Moving Average Crossover Alert Zacks
Nov-08-18 04:05PM  Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction Zacks
Nov-07-18 07:30AM  Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference Business Wire -6.45%
01:30AM  Edited Transcript of AERI earnings conference call or presentation 6-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-06-18 05:55PM  Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:50PM  Aerie: 3Q Earnings Snapshot Associated Press
04:01PM  Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update Business Wire
Oct-30-18 07:30AM  Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018 Business Wire -5.66%
Oct-25-18 08:30AM  Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-24-18 08:11AM  Aerie completes Durham HQ expansion American City Business Journals -8.91%
Oct-23-18 06:30AM  Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters Business Wire
Oct-18-18 12:43PM  Is There An Opportunity With Aerie Pharmaceuticals Incs (NASDAQ:AERI) 48% Undervaluation? Simply Wall St.
Oct-15-18 08:00AM  Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Aerie Pharmaceuticals ACCESSWIRE
Oct-09-18 06:30AM  Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe Business Wire
Sep-25-18 07:30AM  Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference Business Wire
Sep-24-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director Business Wire
Sep-13-18 06:30AM  Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria Business Wire
Sep-12-18 04:01PM  Aerie Pharmaceuticals Appoints David W. Gryska to the Companys Board of Directors Business Wire
08:00AM  Today's Research Reports on Trending Tickers: Momenta Pharmaceuticals and Aerie Pharmaceuticals ACCESSWIRE
Sep-11-18 04:01PM  Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance Business Wire
Sep-10-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing Business Wire
Sep-07-18 09:30AM  Why Is Aerie (AERI) Down 10.6% Since Last Earnings Report? Zacks
Sep-05-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group New Research Emphasizes Economic Growth GlobeNewswire
Aug-29-18 08:00AM  Today's Research Reports on Trending Tickers: Aerie Pharmaceuticals, Inc. and Array BioPharma Inc. ACCESSWIRE
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Foresite Capital Management II10% OwnerAug 20Buy23.2150,0001,160,5002,204,324Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 19Buy23.343,84789,7892,154,324Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 16Buy24.23100,0002,423,0002,150,477Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 14Buy23.73100,0002,373,0002,050,477Aug 14 08:15 PM
Foresite Capital Management II10% OwnerAug 13Buy25.35250,0006,337,3421,310,000Aug 14 08:15 PM
Foresite Capital Management II10% OwnerAug 12Buy24.43189,5554,630,8291,060,000Aug 14 08:15 PM
Kopczynski Casey C.Chief Scientific OfficerFeb 01Sale46.1711,000507,84495,743Feb 01 08:09 PM
Kopczynski Casey C.Chief Scientific OfficerJan 02Sale35.2111,000387,313106,743Jan 02 04:03 PM
Kopczynski Casey C.Chief Scientific OfficerDec 03Sale39.8111,000437,894117,743Dec 04 04:02 PM
Cagle Gerald D.DirectorNov 16Buy41.752,00083,49319,800Nov 19 04:54 PM
Kopczynski Casey C.Chief Scientific OfficerNov 01Sale53.8711,000592,521128,743Nov 02 04:02 PM
Kopczynski Casey C.Chief Scientific OfficerOct 01Sale60.5611,000666,204136,517Oct 01 05:31 PM
RUBINO RICHARD JChief Financial OfficerSep 27Sale60.3716,6051,002,386317,131Sep 28 04:11 PM
RUBINO RICHARD JChief Financial OfficerSep 26Sale60.1950,0003,009,445333,736Sep 28 04:11 PM
RUBINO RICHARD JChief Financial OfficerSep 14Sale60.002120383,736Sep 18 04:03 PM
RUBINO RICHARD JChief Financial OfficerSep 13Sale60.1734,5122,076,608383,738Sep 14 04:04 PM
Kopczynski Casey C.Chief Scientific OfficerSep 04Sale60.0911,000661,024147,517Sep 06 05:03 PM
MITRO THOMAS APresident and COOAug 27Option Exercise3.15190,000598,500241,479Aug 29 04:02 PM
MITRO THOMAS APresident and COOAug 27Sale60.27190,00011,451,00651,479Aug 29 04:02 PM